Aging and Lymphocyte Changes by Immunomodulatory Therapies Impact PML Risk in Multiple Sclerosis Patients

Multiple Sclerosis - United States
doi 10.1177/1352458518775550
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

SAGE Publications

Related search

Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Multiple Sclerosis and Complementary Therapies

Journal of Academic Research in Nursing
2019English

Changes in B- And T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

Archives of Neurology
2010English

Lymphocyte Response Depressive Factor in Multiple Sclerosis

BMJ
1971English

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

Multiple Sclerosis International
Neurology
2015English

Changes in Peripapillary Choroidal Thickness in Patients With Multiple Sclerosis

Acta Ophthalmologica
MedicineOphthalmology
2018English

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

698 Novel Immunomodulatory Therapies for Systemic Sclerosis (SSc) Using Biodegradable Nanoparticles

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Click Lateralization by Multiple Sclerosis Patients

Journal of the Acoustical Society of America
AcousticsUltrasonicsArtsHumanities
1988English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy